Featured Research

from universities, journals, and other organizations

Simpler way to predict heart failure

Date:
November 7, 2012
Source:
Methodist Hospital, Houston
Summary:
Researchers have presented new data that show two biomarkers can improve heart failure risk prediction as part of a simpler model.

The most widely used models for predicting heart failure rely on a complex combination of lifestyle, demographic, and cardiovascular risk factor information.

But today Vijay Nambi, M.D., Ph.D., and Christie Ballantyne, M.D., of The Methodist Hospital Center for Cardiovascular Disease Prevention and the Baylor College of Medicine presented new data that show two biomarkers can improve heart failure risk prediction as part of a simpler model. Their presentation was part of the American Heart Association's Scientific Sessions 2012 in Los Angeles.

Nambi and Ballantyne said their simpler model could use information from lab reports to assess heart failure risk, and could be useful to both patients and doctors.

Nambi and Ballantyne's model uses age, race, and the blood concentrations of two blood biomarkers -- troponin T and NT-proBNP -- to show whether or not a patient is at elevated risk for heart failure.

Applying the model to patient data from the ongoing ARIC study (Atherosclerosis Risk in Communities), the researchers found their simple heart failure risk model was comparable to more complex models that take into account age, race, systolic blood pressure, antihypertensive medication use, smoking or former smoking, diabetes, body-mass index, prevalent coronary heart disease and heart rate.

The protein troponin T is part of the troponin complex and is traditionally used in the diagnosis of heart attacks. NT-proBNP is an inactive peptide fragment left over from the production of brain natiuretic peptide (BNP), a small neuropeptide hormone that has been shown to have value in diagnosing recent and ongoing congestive heart failure. The researchers used both these markers in the prediction of future heart failure (over 10 years) thereby understanding which individuals among a general population are at the highest risk of heart failure. Finally, they showed that adding these biomarkers to the existing models resulted in the best risk prediction models.

This is preliminary data.


Story Source:

The above story is based on materials provided by Methodist Hospital, Houston. Note: Materials may be edited for content and length.


Cite This Page:

Methodist Hospital, Houston. "Simpler way to predict heart failure." ScienceDaily. ScienceDaily, 7 November 2012. <www.sciencedaily.com/releases/2012/11/121107132059.htm>.
Methodist Hospital, Houston. (2012, November 7). Simpler way to predict heart failure. ScienceDaily. Retrieved July 22, 2014 from www.sciencedaily.com/releases/2012/11/121107132059.htm
Methodist Hospital, Houston. "Simpler way to predict heart failure." ScienceDaily. www.sciencedaily.com/releases/2012/11/121107132059.htm (accessed July 22, 2014).

Share This




More Health & Medicine News

Tuesday, July 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins